CRMD CorMedix Forecast, Technical & Fundamental Analysis
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions... Show more
CRMD is expected to report earnings to fall 44.19% to 23 cents per share on August 06
Q2'26
Est.
$0.24
Q1'26
Missed
by $0.02
Q4'25
Missed
by $0.69
Q3'25
Beat
by $0.83
Q2'25
Beat
by $0.12
The last earnings report on May 14 showed earnings per share of 43 cents, missing the estimate of 44 cents. With 4.54M shares outstanding, the current market capitalization sits at 600.94M.
A.I. Advisor
published General Information
General Information
a developer of medical devices for cardiovascular and kidney diseases
A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with ACRV. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then ACRV could also see price increases.
CRMD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on June 25, 2026
CRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where CRMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 196 cases where CRMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CRMD moved out of overbought territory on June 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRMD as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CRMD turned negative on June 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .
CRMD moved below its 50-day moving average on June 25, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.583) is normal, around the industry mean (20.978). P/E Ratio (4.065) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CRMD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (1.903) is also within normal values, averaging (366.957).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CRMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
